The post says these should be established before dual therapy is even considered, and adds that age, diabetes status, and concurrent medications such as other stimulants or antihypertensives further shape the risk picture
These medicines include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management), liraglutide (Victoza for diabetes and Saxenda for weight management), dulaglutide (Trulicity, for diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for weight management), which combines GLP-1 action with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism
The 100mg vial at $100 ($1.00/mg) offers significantly better per-milligram value than the 50mg at 36,800 (736.00 per mg) a 37.5% lower cost per mg for just $20 more upfront
Instead of primarily activating the glucagon-like peptide-1 receptor, it aims to reproduce selected effects of the pancreatic hormone amylin
These are for the dose and formulations used to treat diabetes, but one assumes the approval for obesity doses are coming soon
Malaguarnera M, Pistone G, Astuto M, et al